Cost effectiveness of first line nivolumab plus bevacizumab and chemotherapy for advanced non squamous non small cell lung cancer
Shan Zhao, Shuo Kang · 2025
Read Cost effectiveness of first line nivolumab plus bevacizumab and chemotherapy for advanced non squamous non small cell lung cancer by Shan Zhao, Shuo Kang (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12770627.txt.
Description
Shan Zhao and Shuo Kang weigh the cost-effectiveness of a three-drug first-line plan for advanced lung cancer in a 2025 paper. The plan adds nivolumab to bevacizumab and chemotherapy for non-squamous non-small cell lung cancer. Its value for money in China had not been set out yet.
A partitioned survival model ran patient states in short steps over a long span of years. Clinical data came from a named trial of the plan. Costs and quality weights came from local charges and past studies. Checks that shift key inputs test how firm the result is, and sub-groups are read as well.
Catalog record
| CREATOR | Shan Zhao, Shuo Kang |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 25 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |